RxDoctor Payments Data

Paul Luong, OD

Optometrist · Saint Louis, MONPI 1992155923

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $29,051 of the $44,123 with a category attached, or 65.8%. Bausch & Lomb Americas Inc. accounts for 75.0% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2023 at $13,583 and has fallen 57.9% since, to $5,721 in 2025. Among optometrist clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$44,123in general payments, 2019–2025

Across 163 payments — averaging $270.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb Americas Inc.$33K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$10K
  • Johnson & Johnson Vision Care, Inc.$746
  • Coopervision Inc.$207
  • ABB Con-cise Optical Group LLC$108
  • AbbVie$72
  • plus $96 from 4 others

What the payments were for

  • Consulting fees$3,8759%
  • Speaking & faculty fees$29,05166%
  • Travel & lodging$6,20514%
  • Food & beverage$4,99211%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$44,123 in reported general payments places this provider in the 95th percentile of 1,030 optometrist providers in Missouri.

See all optometrist providers in Missouri

Medicare billing

Part B allowed, 2024
$37,919
Medicare patients
212
Services billed
472

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat12$461
Latanoprost55$427
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha33$282
Dorzolamide Hcl12$230

Paid to pharmacies, not to this prescriber.

Other optometrist in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →